drugset / Trial / NCT00005623

Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

NCT00005623

Phase 3 Completed Barr Laboratories
RandomizedDouble-blindSupportive care

Summary

RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes. PURPOSE: Randomized phase III trial to determine the effectiveness of cyproterone acetate in treating patients who have hot flashes following surgical or chemical castration for prostate cancer.

Timeline

Start
1999-12
Primary completion
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject cyproterone acetate Small molecule Oral

Indications